» Articles » PMID: 25802735

Autism Spectrum Disorder Associated with Low Serotonin in CSF and Mutations in the SLC29A4 Plasma Membrane Monoamine Transporter (PMAT) Gene

Abstract

Background: Patients with autism spectrum disorder (ASD) may have low brain serotonin concentrations as reflected by the serotonin end-metabolite 5-hydroxyindolacetic acid (5HIAA) in cerebrospinal fluid (CSF).

Methods: We sequenced the candidate genes SLC6A4 (SERT), SLC29A4 (PMAT), and GCHFR (GFRP), followed by whole exome analysis.

Results: The known heterozygous p.Gly56Ala mutation in the SLC6A4 gene was equally found in the ASD and control populations. Using a genetic candidate gene approach, we identified, in 8 patients of a cohort of 248 with ASD, a high prevalence (3.2%) of three novel heterozygous non-synonymous mutations within the SLC29A4 plasma membrane monoamine transporter (PMAT) gene, c.86A > G (p.Asp29Gly) in two patients, c.412G > A (p.Ala138Thr) in five patients, and c.978 T > G (p.Asp326Glu) in one patient. Genome analysis of unaffected parents confirmed that these PMAT mutations were not de novo but inherited mutations. Upon analyzing over 15,000 normal control chromosomes, only SLC29A4 c.86A > G was found in 23 alleles (0.14%), while neither c.412G > A (<0.007%) nor c.978 T > G (<0.007%) were observed in all chromosomes analyzed, emphasizing the rareness of the three alterations. Expression of mutations PMAT-p.Ala138Thr and p.Asp326Glu in cellulae revealed significant reduced transport uptake activity towards a variety of substrates including serotonin, dopamine, and 1-methyl-4-phenylpyridinium (MPP(+)), while mutation p.Asp29Gly had reduced transport activity only towards MPP(+). At least two ASD subjects with either the PMAT-Ala138Thr or the PMAT-Asp326Glu mutation with altered serotonin transport activity had, besides low 5HIAA in CSF, elevated serotonin levels in blood and platelets. Moreover, whole exome sequencing revealed additional alterations in these two ASD patients in mainly serotonin-homeostasis genes compared to their non-affected family members.

Conclusions: Our findings link mutations in SLC29A4 to the ASD population although not invariably to low brain serotonin. PMAT dysfunction is speculated to raise serotonin prenatally, exerting a negative feedback inhibition through serotonin receptors on development of serotonin networks and local serotonin synthesis. Exome sequencing of serotonin homeostasis genes in two families illustrated more insight in aberrant serotonin signaling in ASD.

Citing Articles

Role of FPR2 antagonism in alleviating social isolation-induced depression and protecting blood-brain barrier integrity.

Zheng J, Wang H, Wu W, Wang L, Qin M, Zhu L J Neuroinflammation. 2025; 22(1):79.

PMID: 40083006 PMC: 11907847. DOI: 10.1186/s12974-025-03408-4.


Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder.

Kaur H, Karabulut S, Gauld J, Fagot S, Holloway K, Shaw H Psychedelic Med (New Rochelle). 2025; 1(3):166-185.

PMID: 40046567 PMC: 11661495. DOI: 10.1089/psymed.2023.0023.


Single-cell analysis of mesenchymal cells in permeable neural vasculature reveals novel diverse subpopulations of fibroblasts.

Bastedo W, Scott R, Arostegui M, Underhill T Fluids Barriers CNS. 2024; 21(1):31.

PMID: 38575991 PMC: 10996213. DOI: 10.1186/s12987-024-00535-7.


Between Dysbiosis, Maternal Immune Activation and Autism: Is There a Common Pathway?.

Suprunowicz M, Tomaszek N, Urbaniak A, Zackiewicz K, Modzelewski S, Waszkiewicz N Nutrients. 2024; 16(4).

PMID: 38398873 PMC: 10891846. DOI: 10.3390/nu16040549.


Neuroimaging genetics approaches to identify new biomarkers for the early diagnosis of autism spectrum disorder.

Nisar S, Haris M Mol Psychiatry. 2023; 28(12):4995-5008.

PMID: 37069342 PMC: 11041805. DOI: 10.1038/s41380-023-02060-9.


References
1.
Dahlin A, Xia L, Kong W, Hevner R, Wang J . Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience. 2007; 146(3):1193-211. PMC: 2683847. DOI: 10.1016/j.neuroscience.2007.01.072. View

2.
Leabman M, Huang C, DeYoung J, Carlson E, Taylor T, De La Cruz M . Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A. 2003; 100(10):5896-901. PMC: 156298. DOI: 10.1073/pnas.0730857100. View

3.
Castermans D, Volders K, Crepel A, Backx L, De Vos R, Freson K . SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles. Hum Mol Genet. 2010; 19(7):1368-78. DOI: 10.1093/hmg/ddq013. View

4.
Veenstra-VanderWeele J, Jessen T, Thompson B, Carter M, Prasad H, Steiner J . Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse. J Neurodev Disord. 2009; 1(2):158-71. PMC: 2786076. DOI: 10.1007/s11689-009-9020-0. View

5.
Murphy D, Lerner A, Rudnick G, Lesch K . Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv. 2004; 4(2):109-23. DOI: 10.1124/mi.4.2.8. View